FDA Oks Kala Pharma's Eysuvis for dry eye disease

• The FDA has approved Kala Pharmaceuticals' (NASDAQ:KALA) EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
• “The FDA approval of EYSUVIS as the first prescription therapy specifically developed to address the short-term treatment needs of people living with dry eye disease is a major accomplishment for Kala and an important moment for patients, who have been waiting for an FDA-approved, safe, effective and fast-acting therapy,” said Mark Iwicki, Chairman, President and CEO.
• https://seekingalpha.com/news/3626326-fda-oks-kala-pharmas-eysuvis-for-dry-eye-disease